Literature DB >> 6428771

The effects of organic nitrates on prostacyclin biosynthesis and platelet function in humans.

D J Fitzgerald, L Roy, R M Robertson, G A FitzGerald.   

Abstract

The results of prior studies indicate that nitroglycerin stimulates prostacyclin release by cultured endothelium and by the coronary vasculature in vivo. However, the accuracy of these findings in coronary vasculature relies on plasma samples obtained from the circulation via cardiac catheters, a procedure we have shown to stimulate prostacyclin release, thereby confounding interpretation of drug action. We studied the effects of short-acting (nitroglycerin) and long-acting (isosorbide dinitrate) nitrates on a noninvasive index of prostacyclin synthesis, excretion of urinary 2,3-dinor-6-keto-PGF1 alpha. Nitroglycerin was infused into six subjects to either a maximum of 480 micrograms/min or until mean arterial pressure fell by 20 mm Hg. Urine was collected for negative ion chemical ionization gas chromatographic, mass spectrometric analysis before and during the nitroglycerin infusion and for two 2 hr periods after nitroglycerin. The peak nitroglycerin infusion rate was 387 +/- 67 micrograms/min, which caused a fall in supine blood pressure (systolic/diastolic) of 11 +/- 5/14 +/- 4 mm Hg and a 12 +/- 3 beats/min increase in heart rate. Excretion of 2,3-dinor-6-keto-PGF1 alpha (pg/mg creatinine) was unchanged from control infusion values (106 +/- 19.5) either during (123 +/- 21) or after (134 +/- 14.6; 139 +/- 36) nitroglycerin infusion. Platelet aggregation to arachidonic acid (0.33 to 1.33 microM) and epinephrine (1 to 10 microM) ex vivo was inhibited in only one subject in whom excretion of 2,3-dinor-6-keto-PGF1 alpha was unaltered. Serum thromboxane B2 was not changed by nitroglycerin infusion.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6428771     DOI: 10.1161/01.cir.70.2.297

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  12 in total

Review 1.  Recognition and treatment of unstable angina.

Authors:  C Brunelli; P Spallarossa; P Rossettin; S Caponnetto
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

Review 2.  Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.

Authors:  S Silber
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Prostaglandins, other eicosanoids and endothelial cells.

Authors:  K Schrör
Journal:  Basic Res Cardiol       Date:  1985 Sep-Oct       Impact factor: 17.165

4.  [The heart as an endocrine organ: the discovery of a new hormone].

Authors:  R Gerzer
Journal:  Klin Wochenschr       Date:  1985-06-18

5.  Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids.

Authors:  T A Swierkosz; J A Mitchell; T D Warner; R M Botting; J R Vane
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

Review 6.  Management of stable angina.

Authors:  A Jain; V Wadehra; A D Timmis
Journal:  Postgrad Med J       Date:  2003-06       Impact factor: 2.401

Review 7.  Use of nitrates in the treatment of unstable and variant angina.

Authors:  R Nordlander
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 8.  The high-risk unstable angina patient. An approach to treatment.

Authors:  S Kar; Y Wakida; R Nordlander
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

9.  Effects of treatment with oral isosorbide dinitrate on platelet function in vivo; a double-blind placebo-controlled study in patients with stable angina pectoris.

Authors:  N H Wallén; A Andersson; P Hjemdahl
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

10.  Effects of an oral dose of isosorbide dinitrate on platelet function and fibrinolysis in healthy volunteers.

Authors:  N H Wallén; P T Larsson; A Bröijersén; A Andersson; P Hjemdahl
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.